-
1Academic Journal
Authors: A. O. Osichkina, E. D. Kasyanov, G. V. Rukavishnikov, N. I. Shova, V. A. Mikhailov, G. E. Mazo, А. О. Осичкина, Е. Д. Касьянов, Г. В. Рукавишников, Н. И. Шова, В. А. Михайлов, Г. Э. Мазо
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 2 (2024); 54-59 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 2 (2024); 54-59 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-2
Subject Terms: эпилепсия, mood disorders, bipolar disorder, depression, interictal dysphoric disorder, epilepsy, расстройства настроения, биполярное расстройство, депрессия, межприступное дисфорическое расстройство
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/2232/1650; Lu E, Pyatka N, Burant CJ, Sajatovic M. Systematic Literature Review of Psychiatric Comorbidities in Adults with Epilepsy. J Clin Neurol. 2021 Apr;17(2):176-86. doi:10.3988/jcn.2021.17.2.176; Киссин МЯ, Селютина ЕВ. Причины развития нозогенных психических расстройств у пациентов с эпилепсией. Эпилепсия и пароксизмальные состояния. 2019;11(3):293-7. doi:10.17749/2077-8333.2019.11.3.293-297; Fiest KM, Dykeman J, Patten SB, et al. Depression in epilepsy: a systematic review and meta-analysis. Neurology. 2013 Feb 5;80(6):590-9. doi:10.1212/WNL.0b013e31827b1ae0. Epub 2012 Nov 21.; Li J, Ledoux-Hutchinson L, Toffa DH. Prevalence of Bipolar Symptoms or Disorder in Epilepsy: A Systematic Review and Metaanalysis. Neurology. 2022 May 10;98(19):e1913-e1922. doi:10.1212/WNL.0000000000200186. Epub 2022 Mar 15.; Hermann BP, Seidenberg M, Bell B. Psychiatric comorbidity in chronic epilepsy: identification, consequences, and treatment of major depression. Epilepsia. 2000;41 Suppl 2:S31-41. doi:10.1111/j.1528-1157.2000.tb01522.x; Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):593-602. doi:10.1001/archpsyc.62.6.593. Erratum in: Arch Gen Psychiatry. 2005 Jul;62(7):768.; Kanner AM, Saporta AS, Kim DH, et al; Human Epilepsy Project. Mood and Anxiety Disorders and Suicidality in Patients With Newly Diagnosed Focal Epilepsy: An Analysis of a Complex Comorbidity. Neurology. 2023 Mar 14;100(11):e1123-e1134. doi:10.1212/WNL.0000000000201671. Epub 2022 Dec 20.; Blumer D, Montouris G, Davies K. The interictal dysphoric disorder: recognition, pathogenesis, and treatment of the major psychiatric disorder of epilepsy. Epilepsy Behav. 2004 Dec;5(6):826-40. doi:10.1016/j.yebeh.2004.08.003; Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 2007;30(7):555-67. doi:10.2165/00002018-200730070-00001; Ettinger AB, Kanner AM. Psychiatric issues in epilepsy: a practical guide to diagnosis and treatment. London: Wolters Kluwer Health/Lippincott Williams and Wilkins; 2007.; Kanner AM, Schachter SC, eds. Psychiatric controversies in epilepsy. San Diego: Academic Press; 2008.; Teixeira AL. Peri-Ictal and Para-Ictal Psychiatric Phenomena: A Relatively Common Yet Unrecognized Disorder. Curr Top Behav Neurosci. 2022;55:171-81. doi:10.1007/7854_2021_223; Besag FMC, Vasey MJ. Prodrome in epilepsy. Epilepsy Behav. 2018 Jun;83:219-33. doi:10.1016/j.yebeh.2018.03.019. Epub 2018 Apr 10.; Kraepelin E. Psychiatrische Bewegungsbilder. Zeitschriftfür die gesamte Neurologie und Psychiatrie. 1923;85(1):609-13.; Bleuler E. Lehrbuch der Psychiatrie. 8th ed. Berlin: Springer; 1949.; Zinchuk M, Kustov G, Pashnin E, et al. Interictal dysphoric disorder in people with and without epilepsy. Epilepsia. 2021 Jun;62(6):1382-90. doi:10.1111/epi.16902. Epub 2021 Apr 15.; Wiglusz MS, Landowski J, Cubala WJ. Interictal dysphoric disorder of epilepsy: A continuing diagnostic challenge. Epilepsy Behav. 2019 Jun;95:34-8. doi:10.1016/j.yebeh.2019.03.036. Epub 2019 Apr 22.; Amiri M, Hansen CP. The interictal dysphoric disorder in patients with epilepsy: A doubtful disorder lacking diagnostic tools. Seizure. 2015 Jan;24:70-6. doi:10.1016/j.seizure.2014.08.009. Epub 2014 Aug 29.; Suda T, Tatsuzawa Y, Mogi T, Yoshino A. Interictal dysphoric disorder in patients with localization-related epilepsy: Diagnostic relationships with DSM-IV psychiatric disorders and the impact of psychosocial burden. Epilepsy Behav. 2016 Jan;54:142-7. doi:10.1016/j.yebeh.2015.11.020. Epub 2015 Dec 17.; Mula M, Jauch R, Cavanna A, et al. Clinical and psychopathological definition of the interictal dysphoric disorder of epilepsy. Epilepsia. 2008 Apr;49(4):650-6. doi:10.1111/j.1528-1167.2007.01434.x. Epub 2007 Dec 18.; Kanner AM, Schachter SC, Barry JJ, et al. Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. Epilepsy Behav. 2012 Jun;24(2):156-68. doi:10.1016/j.yebeh.2012.01.007. Erratum in: Epilepsy Behav. 2014 Mar;32:170; Кустов ГВ, Акжигитов РГ, Лебедева АВ и др. Межприступное дисфорическое расстройство: современное состояние проблемы. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2017;117(9-2):39-43. doi:10.17116/jnevro20171179239-43; Kanner AM, Kozak AM, Frey M. The Use of Sertraline in Patients with Epilepsy: Is It Safe? Epilepsy Behav. 2000 Apr;1(2):100-5. doi:10.1006/ebeh.2000.0050; Miller JM, Kustra RP, Vuong A, et al. Depressive symptoms in epilepsy: prevalence, impact, aetiology, biological correlates and effect of treatment with antiepileptic drugs. Drugs. 2008;68(11):1493-509. doi:10.2165/00003495-200868110-00003; Yang Y, Yang M, Shi Q, et al. Risk factors for depression in patients with epilepsy: A meta-analysis. Epilepsy Behav. 2020 May;106:107030. doi:10.1016/j.yebeh.2020.107030. Epub 2020 Apr 2.; Ettinger AB, Good MB, Manjunath R, et al. The relationship of depression to antiepileptic drug adherence and quality of life in epilepsy. Epilepsy Behav. 2014 Jul;36:138-43. doi:10.1016/j.yebeh.2014.05.011. Epub 2014 Jun 11.; Wiglusz MS, Landowski J, Cubala WJ, Agius M. Overlapping phenomena of bipolar disorder and epilepsy – a common pharmacological pathway. Psychiatr Danub. 2015 Sep;27 Suppl 1:S177-81.; Akinci E, Basaran S, Tas H. Evaluation of Depression with Mixed Features and Bipolarity Screening in Patients with Epilepsy. Psychiatry Clin Psychopharmacol. 2021;31:77-82. doi:10.5152/pcp.2021.20163; Kanner AM, Soto A, Gross-Kanner H. Prevalence and clinical characteristics of postictal psychiatric symptoms in partial epilepsy. Neurology. 2004 Mar 9;62(5):708-13. doi:10.1212/01.wnl.0000113763.11862.26; Jones JE, Hermann BP, Barry JJ, et al. Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy Behav. 2003 Oct;4 Suppl 3:S31-8. doi:10.1016/j.yebeh.2003.08.019; Christensen J, Vestergaard M, Mortensen PB, et al. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol. 2007 Aug;6(8):693-8. doi:10.1016/S1474-4422(07)70175-8; Powell J, Geddes J, Deeks J, et al. Suicide in psychiatric hospital in-patients. Risk factors and their predictive power. Br J Psychiatry. 2000 Mar;176:266-72. doi:10.1192/bjp.176.3.266; Mula M, Sander JW. Suicide risk in people with epilepsy taking antiepileptic drugs. Bipolar Disord. 2013 Aug;15(5):622-7. doi:10.1111/bdi.12091. Epub 2013 Jun 12.; Andersohn F, Schade R, Willich SN, Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology. 2010 Jul 27;75(4):335-40. doi:10.1212/WNL.0b013e3181ea157e; Machado RA, Espinosa AG, Melendrez D, et al. Suicidal risk and suicide attempts in people treated with antiepileptic drugs for epilepsy. Seizure. 2011 May;20(4):280-4. doi:10.1016/j.seizure.2010.12.010. Epub 2011 Jan 26.; Klein P, Devinsky O, French J, et al. Suicidality Risk of Newer Antiseizure Medications: A Meta-analysis. JAMA Neurol. 2021 Sep 1;78(9):1118-27. doi:10.1001/jamaneurol.2021.2480; Ferrer P, Ballarin E, Sabate M, et al. Antiepileptic drugs and suicide: a systematic review of adverse effects. Neuroepidemiology. 2014;42(2):107-20. doi:10.1159/000356807. Epub 2014 Jan 3.; Mula M. Suicidality and antiepileptic drugs in people with epilepsy: an update. Expert Rev Neurother. 2022 May;22(5):405-10. doi:10.1080/14737175.2022.2064744. Epub 2022 Apr 13.; Quiske A, Helmstaedter C, Lux S, Elger CE. Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res. 2000 Apr;39(2):121-5. doi:10.1016/s0920-1211(99)00117-5; Kanner AM, Balabanov A. Depression and epilepsy: how closely related are they? Neurology. 2002 Apr 23;58(8 Suppl 5):S27-39. doi:10.1212/wnl.58.8_suppl_5.s27; Sheline YI. Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry. 2003 Aug 1;54(3):338-52. doi:10.1016/s0006-3223(03)00347-0; Kanner A. Peri-ictal psychiatric phenomena. In: Trimble M, Schmitz B, eds. The Neuropsychiatry of Epilepsy. Cambridge: Cambridge University Press; 2011. P. 57-66. doi:10.1017/CBO9780511977145.007; Kanner AM, Wuu J, Barry J, et al. Atypical depressive episodes in epilepsy: a study of their clinical characteristics and impact on quality of life. Neurology. 2004;62(Suppl 5):A249.; Mula M, Brodie MJ, de Toffol B, et al. ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. Epilepsia. 2022 Feb;63(2):316-34. doi:10.1111/epi.17140. Epub 2021 Dec 5.
-
2Academic Journal
Authors: E. A. Strel’tsov
Source: Медицинский вестник Юга России, Vol 12, Iss 3, Pp 32-35 (2021)
Subject Terms: обзор, Medicine (General), 03 medical and health sciences, атипичные антипсихотики, R5-920, 0302 clinical medicine, кари- празин, биполярное расстройство, депрессивный эпизод, луразидон, 3. Good health
-
3Report
-
4
-
5
-
6Academic Journal
Subject Terms: bipolar disorder, substance use disorder, антипсихотическое средство, cariprazine, биполярное расстройство, карипразин, partial agonist, психофармакотерапия, расстройство вследствие употребления психоактивных веществ, частичный агонист, psychopharmacotherapy, 3. Good health, antipsychotic
-
7
-
8Academic Journal
Authors: E. D. Kasyanov, T. V. Zhilyaeva, G. E. Maso, Е. Д. Касьянов, Т. В. Жиляева, Г. Э. Мазо
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 5 (2022); 13-21 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 5 (2022); 13-21 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-5
Subject Terms: MTHFR, bipolar disorder, family research, one-carbon metabolism, биполярное расстройство, семейное исследование, одноуглеродный метаболизм
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1885/1450; https://nnp.ima-press.net/nnp/article/view/1885/1451; Касьянов ЕД, Рукавишников ГВ, Кибитов АА и др. Современные подходы к изучению генетики депрессии: возможности и ограничения. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2021;121(5-2):61-6. doi:10.17116/jnevro202112105261.; Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Primers. 2018 Mar 8;4:18008. doi:10.1038/nrdp.2018.8; Smoller JW, Finn CT. Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet. 2003 Nov 15;123C(1):48-58. doi:10.1002/ajmg.c.20013; Lang UE, Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem. 2013;31(6):761-77. doi:10.1159/000350094. Epub 2013 May 31.; Amare AT, Schubert KO, Klingler-Hoffmann M, et al. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. Transl Psychiatry. 2017;7(1):e1007. Available from: http://creativecommons.org/licenses/by/4.0/; Rukavishnikov G, Kasyanov E, Zhilyaeva T, et al. Inherited Metabolic Diseases as a Multisystem Model of Mental Disorders Research. J Inborn Errors Metabol Screen. 2021;9:e20200015. doi:10.1590/2326-4594- jiems-2020-0015. Epub Feb 12, 2021.; Fiedorowicz JG, He J, Merikangas KR. The association between mood and anxiety disorders with vascular diseases and risk factors in a nationally representative sample. J Psychosom Res. 2011 Feb;70(2):145-54. doi:10.1016/j.jpsychores.2010.07.010. Epub 2010 Sep 18.; Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163-80. doi:10.1002/wps.20420; Walker J, Burke K, Wanat M, et al. The prevalence of depression in general hospital inpatients: a systematic review and meta-analysis of interview-based studies. Psychol Med. 2018;48(14):2285-98. doi:10.1017/S0033291718000624; Незнанов НГ, Мазо ГЭ, Рукавишников ГВ, Кибитов АО. Депрессия как предиктор соматических заболеваний: патофизиологические предпосылки и генетический риск. Успехи физиологических наук. 2017;48(4):29-39.; Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across human diseases and traits. Nat Genet. 2015;47(11):1236-41. doi:10.1038/ng.3406; Zhu X, Need AC, Petrovski S, Goldstein DB. One gene, many neuropsychiatric disorders: lessons from Mendelian diseases. Nat Neurosci. 2014;17(6):773-81. doi:10.1038/nn.3713; Kember RL, Hou L, Ji X, et al. Genetic pleiotropy between mood disorders, metabolic, and endocrine traits in a multigenerational pedigree. Transl Psychiatry. 2018;8(1):218. doi:10.1038/s41398-018-0226-3; Bhatia P, Singh N. Homocysteine excess: delineating the possible mechanism of neurotoxicity and depression. Fundam Clin Pharmacol. 2015 Dec;29(6):522-8. doi:10.1111/fcp.12145. Epub 2015 Sep 17.; Ducker GS, Rabinowitz JD. One-Carbon Metabolism in Health and Disease. Cell Metab. 2017 Jan 10;25(1):27-42. doi:10.1016/j.cmet.2016.08.009. Epub 2016 Sep 15.; Wan L, Li Y, Zhang Z, et al. Methylenetetrahydrofolate reductase and psychiatric diseases. Transl Psychiatry. 2018;8(1):242. doi:10.1038/s41398-018-0276-6; Жиляева ТВ, Сергеева АВ, Благонравова АС и др. Нарушения одноуглеродного метаболизма при шизофрении: генетические и терапевтические аспекты. Нейрохимия. 2019;36(2):91-100. doi:10.1134/S1027813319020158.; Holmes MV, Newcombe P, Hubacek JA, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet. 2011;378(9791):584-94. doi:10.1016/S0140-6736(11)60872-6; Ilhan N, Kucuksu M, Kaman D, et al. The 677 C/T MTHFR polymorphism is associated with essential hypertension, coronary artery disease, and higher homocysteine levels. Arch Med Res. 2008 Jan;39(1):125-30. doi:10.1016/j.arcmed.2007.07.009. Epub 2007 Oct 15.; Van der Wal HH, Comin-Colet J, Klip IT, et al. Vitamin B12 and folate deficiency in chronic heart failure. Heart. 2015;101(4):302-10. doi:10.1136/heartjnl2014-306022; Fu Y, Wang X, Kong W. Hyperhomocysteinaemia and vascular injury: advances in mechanisms and drug targets. Br J Pharmacol. 2018 Apr;175(8):1173-89. doi:10.1111/bph.13988. Epub 2017 Sep 22.; Sharma M, Tiwari M, Tiwari RK. Hyperhomocysteinemia: Impact on Neurodegenerative Diseases. Basic Clin Pharmacol Toxicol. 2015 Nov;117(5):287-96. doi:10.1111/bcpt.12424. Epub 2015 Jun 19.; De-Regil LM, Pena-Rosas JP, Fernandez-Gaxiola AC, Rayco-Solon P. Effects and safety of periconceptional oral folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2015 Dec 14;2015(12):CD007950. doi:10.1002/14651858.CD007950.pub3; Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur J Med Genet. 2015 Jan;58(1):1-10. doi:10.1016/j.ejmg.2014.10.004. Epub 2014 Nov 4.; Reif A, Pfuhlmann B, Lesch KP. Homocysteinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Sep;29(7):1162-8. doi:10.1016/j.pnpbp.2005.06.027; Zintzaras E. C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: a meta-analysis of genetic association studies. Psychiatr Genet. 2006 Jun;16(3):105-15. doi:10.1097/01.ypg.0000199444.77291.e2; Kempisty B, Bober A, Luczak M, et al. Distribution of 1298A>C polymorphism of methylenetetrahydrofolate reductase gene in patients with bipolar disorder and schizophrenia. Eur Psychiatry. 2007;22(1):39-43. doi:10.1016/j.eurpsy.2006.11.003; Peerbooms OL, van Os J, Drukker M, et al; MTHFR in Psychiatry Group. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability? Brain Behav Immun. 2011;25(8):1530-43. doi:10.1016/j.bbi.2010.12.006; Kempisty B, Mostowska A, Gorska I, et al. Association of 677C>T polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene with bipolar disorder and schizophrenia. Neurosci Lett. 2006 Jun 12;400(3):267-71. doi:10.1016/j.neulet.2006.02.055. Epub 2006 Mar 20.; Chen Z, Liu Y, Zhang D, et al. C677T methylenetetrahydrofolate reductase gene polymorphisms in bipolar disorder: an association study in the Chinese population and a metaanalysis of genetic association studies. Neurosci Lett. 2009;449(1):48-51. doi:10.1016/j.neulet.2008.10.077; Slopien R, Jasniewicz K, Meczekalski B, et al. Polymorphic variants of genes encoding MTHFR, MTR, and MTHFD1 and the risk of depression in postmenopausal women in Poland. Maturitas. 2008 Nov 20;61(3):252-5. doi:10.1016/j.maturitas.2008.08.002. Epub 2008 Sep 17.; Yang YH, Chiu CC, Teng HW, et al. Methionine synthase 2756AA polymorphism is associated with the risk of cognitive impairment in patients with late-life depression. Asia-Pacific Psychiatry. 2017;9(1):e12242. doi:10.1111/appy.12242; McGrane IR, Mertens S. Depression and pharmacogenetics: A psychiatric pharmacist's perspective. Arch Psychiatr Nurs. 2018 Jun;32(3):329-30. doi:10.1016/j.apnu.2018.02.003. Epub 2018 Feb 13.; Jamerson BD, Payne ME, Garrett ME, et al. Folate metabolism genes, dietary folate and response to antidepressant medications in late-life depression. Int J Geriatr Psychiatry. 2013;28(9):925-32. doi:10.1002/gps.3899; Permoda-Osip A, Dmitrzak-Weglarz M, Hauser J, Rybakowski JK. Are genes connected with homocysteine metabolism associated with bipolar disorder? Neuropsychobiology. 2014;69(2):107-11. doi:10.1159/000358091. Epub 2014 Feb 27.; Ozbek Z, Kucukali CI, Ozkok E, et al. Effect of the methylenetetrahydrofolate reductase gene polymorphisms on homocysteine, folate and vitamin B12 in patients with bipolar disorder and relatives. Progr Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1331-7. doi:10.1016/j.pnpbp.2008.04.016; Nelson JC. The evolving story of folate in depression and the therapeutic potential of l-methylfolate. Am J Psychiatry. 2012 Dec;169(12):1223-5. doi:10.1176/appi.ajp.2012.12091207
-
9Academic Journal
-
10Academic Journal
Authors: Игорь Борисович Заболотских, А. И. Грицан, К. М. Лебединский, В. В. Мясникова, А. Е. Муронов, К. Г. Шаповалов
Source: Вестник интенсивной терапии, Iss 1 (2021)
Subject Terms: психические заболевания, депрессия, биполярное расстройство, шизофрения, тревожные расстройства, анестезия, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
File Description: electronic resource
-
11Academic Journal
Authors: D. V. Romanov, P. G. Yuzbashyan, Д. В. Романов, П. Г. Юзбашян
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 3 (2020); 117-122 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 3 (2020); 117-122 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-3
Subject Terms: антинегативный эффект, glutamate, NMDA receptor, mental disorders, schizophrenia, depression, bipolar disorder, obsessive disorder, precognitive effect, antinegative effect, глутамат, NMDA-рецептор, психические расстройства, шизофрения, депрессия, биполярное расстройство, обсессивное расстройство, прокогнитивный эффект
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1375/1068; Alzheimer's Association encouraged by FDA approval of memantine, October 17, 2003. 5 EMEA (European Medicines Agency), EPAR, Axura, July 4, 2002 http://www.eudra.org/humandocs/humans/epar/axura/axura.htm.; Laver K, Cumming RG, Dyer SM, et al. Clinical practice guidelines for dementia in Australia. Med J Aust. 2016 Mar 21;204(5): 191-3. doi:10.5694/mja15.01339.; Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. Eur J Neurol. 2015 Jun;22(6):889-98. doi:10.1111/ene.12707. Epub 2015 Mar 25.; National Institute for Health and Care Excellence (Great Britain). Dementia: Assessment, Management and Support for People Living with Dementia and Their Carers.; 2018. http://www.ncbi.nlm.nih.gov/books/NBK513207/; Areosa SA, Sherriff F. Memantine for dementia. Cochrane Database Syst Rev. 2003;(3):CD003154. doi:10.1002/14651858.CD003154.; McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154. doi:10.1002/14651858.CD003154.pub6.; Johnson J, Kotermanski S. Mechanism of action of memantine. Curr Opin Pharmacol. 2006 Feb;6(1):61-7. doi:10.1016/j.coph.2005.09.007. Epub 2005 Dec 20.; Chen H, Pellegrini J, Aggarwal S, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci. 1992 Nov;12(11): 4427-36. doi:10.1523/JNEUROSCI.12-11-04427.1992.; Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Alzheimers Dis. 2004 Dec;6(6 Suppl):S61-74. doi:10.3233/jad-2004-6s610.; Moriguchi S, Ishizuka T, Yabuki Y, et al. Blockade of the KATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer's disease therapy. Mol Psychiatry. 2018 Feb;23(2):211-221. doi:10.1038/mp.2016.187. Epub 2016 Oct 25.; Rammes G, Rupprecht R, Ferrari U, et al. The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett. 2001;306(1-2):81-4. doi:10.1016/S0304-3940(01)01872-9.; Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse. 2008 Feb;62(2):149-53. doi:10.1002/syn.20472.; Aracava Y, Pereira EFR, Maelicke A, Albuquerque EX. Memantine Blocks a7 * Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons. J Pharmacol Exp Ther. 2005 Mar;312(3):1195-205. doi:10.1124/jpet.104.077172. Epub 2004 Nov 2.; Madeira C, Alheira FV, Calcia MA, et al. Blood Levels of Glutamate and Glutamine in Recent Onset and Chronic Schizophrenia. Front Psychiatry. 2018 Dec 19;9:713. doi:10.3389/fpsyt.2018.00713. eCollection 2018.; McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020 Feb;19(1):15-33. doi:10.1002/wps.20693.; Blacker CJ, Millischer V, Webb LM, et al. EAAT2 as a Research Target in Bipolar Disorder and Unipolar Depression: A Systematic Review. Mol Neuropsychiatry. 2020 Apr;5(Suppl 1):44-59. doi:10.1159/000501885. Epub 2019 Jul 23.; Blacker CJ, Lewis CP, Frye MA, Veldic M. Metabotropic glutamate receptors as emerging research targets in bipolar disorder. Psychiatry Res. 2017 Nov;257:327-337. doi:10.1016/j.psychres.2017.07.059. Epub 2017 Jul 31.; Soeiro-de-Souza MG, Otaduy MCG, Machado-Vieira R, et al. Anterior Cingulate Cortex Glutamatergic Metabolites and Mood Stabilizers in Euthymic Bipolar I Disorder Patients: A Proton Magnetic Resonance Spectroscopy Study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Dec;3(12): 985-91. doi:10.1016/j.bpsc.2018.02.007. Epub 2018 Mar 31; Inoshita M, Umehara H, Watanabe S, et al. Elevated peripheral blood glutamate levels in major depressive disorder. Neuropsychiatr Dis Treat. 2018 Apr 6;14:945-53. doi:10.2147/NDT.S159855. eCollection 2018.; Shirayama Y, Takahashi M, Osone F, et al. Myo-inositol, Glutamate, and Glutamine in the Prefrontal Cortex, Hippocampus, and Amygdala in Major Depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Mar;2(2):196-204. doi:10.1016/j.bpsc.2016.11.006. Epub 2016 Dec 2.; Averill LA, Abdallah CG, Fenton LR, et al. Early life stress and glutamate neurotransmission in major depressive disorder. Eur Neuropsychopharmacol. 2020 Jun;35:71-80. doi:10.1016/j.euroneuro.2020.03.015. Epub 2020 May 15.; Karthik S, Sharma LP, Narayanaswamy JC. Investigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives. Neuropsychiatr Dis Treat. 2020 Apr 17;16:1003-13. doi:10.2147/NDT.S211703. eCollection 2020.; Гаврилова СИ. Мемантин в лечении болезни Альцгеймера: 20 лет клинического применения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(6-2):10-8.; Михайлова НМ. Мемантин (акатинол) в лечении сосудистой деменции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(11-2):82-90.; Беккер РА, Быков ЮВ. Мемантин: обзор применения в неврологии. Психиатрия и психофармакотерапия им. П.Б. Ганнушкина. 2017;(1):34-43.; Беккер РА, Быков ЮВ. Мемантин: возможности и перспективы применения в психиатрии (обзор современных данных). Психиатрия и психофармакотерапия им. П.Б. Ганнушкина. 2016;(4):42-51.; Amidfar M, Khiabany M, Kohi A, et al. Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. J Clin Pharm Ther. 2017 Feb;42(1):44-50. doi:10.1111/jcpt.12469. Epub 2016 Nov 3.; De Lucena D, Fernandes BS, Berk M, et al. Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Trial With Memantine as Add-On Therapy to Clozapine. J Clin Psychiatry. 2009 Oct;70(10):1416-23. doi:10.4088/JCP.08m04935gry.; Fakhri A, Pakseresht S, Haghdoost MR, et al. Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study. Acta Med Iran. 2016 Nov;54(11):696-703.; Mazinani R, Nejati S, Khodaei M. Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial. Psychiatry Res. 2017 Jan;247:291-95. doi:10.1016/j.psychres.2016.09.028. Epub 2016 Sep 21.; Omranifard V, Rajabi F, Mohammadian-Sichani M, Maracy M. The effect of add-on memantine on global function and quality of life in schizophrenia: A randomized, doubleblind, controlled, clinical trial. Adv Biomed Res. 2015 Sep 28;4:211. doi:10.4103/2277-9175.166148. eCollection 2015.; Omranifard V, Rajabi F, Mohammadian-Sichani M, Maracy MR. The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a double blind, randomized, controlled trial. Actas Esp Psiquiatr. 2017 May;45(3):108-15. Epub 2017 May 1.; Rezaei F, Mohammad-karimi M, Seddighi S, et al. Memantine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychopharmacol. 2013 Jun;33(3):336-42. doi:10.1097/JCP.0b013e31828b50a7.; Sahraian A, Jahromi LR, Ghanizadeh A, Mowla A. Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Clin Psychopharmacol. 2017 Apr;37(2):246-49. doi:10.1097/JCP000.0000000000651.; Anand A, Gunn AD, Barkay G, et al. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial: Memantine augmentation of lamotrigine in bipolar depression. Bipolar Disord. 2012 Feb;14(1):64-70. doi:10.1111/j.1399-5618.2011.00971.x.; Lee JG, Lee SW, Lee BJ, et al. Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study. Psychiatry Investig. 2012 Jun;9(2): 166-73. doi:10.4306/pi.2012.9.2.166. Epub 2012 May 22.; Lieberman JA, Papadakis K, Csernansky J, et al. A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia. Neuropsychopharmacology. 2009 Apr;34(5):1322-9. doi:10.1038/npp.2008.200. Epub 2008 Nov 12.; Omranifard V, Shirzadi E, Samandari S, et al. Memantine add on to citalopram in elderly patients with depression: A double-blind placebo-controlled study. J Res Med Sci. 2014 Jun;19(6):525-30.; Smith EG, Deligiannidis KM, Ulbricht CM, et al. Antidepressant Augmentation Using the N -Methyl- d -Aspartate Antagonist Memantine: A Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Psychiatry. 2013 Oct;74(10):966-73. doi:10.4088/JCP.12m08252.; Осадший ЮЮ, Арчаков ДС, Тараканова ЕА, Вобленко РА. Рандомизированное простое слепое плацебо-контролируемое исследование мемантина как дополнительного средства для лечения негативных симптомов при параноидной шизофрении. Современная терапия психических расстройств. 2015(3):2-7.; Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1362-74. doi:10.1016/j.pnpbp.2008.01.008. Epub 2008 Jan 17.; McCloud T, Caddy C, Jochim J, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev. 2015 Sep 29;(9): CD011611. doi:10.1002/14651858.CD011611.pub2.; Caddy C, Amit BH, McCloud TL, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. 2015 Sep 23;(9):CD011612. doi:10.1002/14651858.CD011612.pub2.; Kishi T, Matsunaga S, Iwata N. A Meta-Analysis of Memantine for Depression. J Alzheimer's Dis. 2017;57(1):113-21. doi:10.3233/JAD-161251.; Marinova Z, Chuang DM, Fineberg N. Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder. Curr Neuropharmacol. 2017;15(7): 977-95. doi:10.2174/1570159X15666170320104237.; Ghaleiha A, Entezari N, Modabbernia A, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013 Feb;47(2):175-80. doi:10.1016/j.jpsychires.2012.09.015. Epub 2012 Oct 9.; Haghighi M, Jahangard L, Mohammad-Beigi H, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl). 2013 Aug; 228(4):633-40. doi:10.1007/s00213-013-3067-z. Epub 2013 Mar 23.; Kishi T, Iwata N. NMDA receptor antagonists interventions in schizophrenia: Metaanalysis of randomized, placebo-controlled trials. J Psychiatr Res. 2013 Sep;47(9):1143-9. doi:10.1016/j.jpsychires.2013.04.013. Epub 2013 May 18.; Zheng W, Li XH, Yang XH, et al. Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Psychol Med. 2018 Jan;48(1):72-81. doi:10.1017/S0033291717001271. Epub 2017 May 22.; Kishi T, Matsuda Y, Iwata N. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Psychopharmacology (Berl). 2017 Jul;234(14):2113-25. doi:10.1007/s00213-017-4616-7. Epub 2017 May 15.; Zheng W, Li XH, Yang XH, et al. Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Psychol Med. 2018 Jan;48(1): 72-81. doi:10.1017/S0033291717001271. Epub 2017 May 22.; Singh SP, Singh V. Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia. CNS Drugs. 2011 Oct 1;25(10):859-85. doi:10.2165/11586650-000000000-00000.; Zheng W, Zhu XM, Zhang QE, et al. Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials. Schizophr Res. 2019 Jul;209:12-21. doi:10.1016/j.schres.2019.05.019. Epub 2019 Jun 1.; Kishi T, Ikuta T, Oya K, et al. Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis. Int J Neuropsycho-pharmacol. 2018 Aug 1;21(8):748-757. doi:10.1093/ijnp/pyy045.; Hassanpour F, Zarghami M, Mouodi S, et al. Adjunctive Memantine Treatment of Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Study. J Clin Psychopharmacol. Nov/Dec 2019;39(6):634-38. doi:10.1097/JCP.0000000000001115.; Veerman SRT, Schulte PFJ, Deijen JB, de Haan L. Adjunctive memantine in clozapine-treated refractory schizophrenia: an openlabel 1-year extension study. Psychol Med. 2017 Jan;47(2):363-75. doi:10.1017/S0033291716002476. Epub 2016 Oct 25.; Veerman SRT, Schulte PFJ, Smith JD, de Haan L. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychol Med. 2016 Jul;46(9):1909-21. doi:10.1017/S0033291716000398. Epub 2016 Apr 6.; Bhakta SG, Chou HH, Rana B, et al. Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy. Psychopharmacology (Berl). 2016 Jun;233(12):2399-410. doi:10.1007/s00213-016-4291-0. Epub 2016 Apr 13.
-
12Academic Journal
Authors: Морозова, М.А., Алексеев, А.А., Рупчев, Г.Е.
Source: Современная терапия психических расстройств, Vol 2017, Iss 2 (41), Pp 40-43 (2017)
Subject Terms: алимемазин, шизофрения, антипсихотики, биполярное расстройство, перевод на новую терапию, вегетативный дисбаланс, психопатоподобные расстройства, ремиссия, Neurology. Diseases of the nervous system, RC346-429, Medicine
File Description: electronic resource
-
13Academic Journal
Authors: Федотов, Дмитрий, Костюкова, Елена, Мосолов, Сергей
Subject Terms: БИПОЛЯРНОЕ РАССТРОЙСТВО,ПРОФИЛАКТИЧЕСКАЯ ТЕРАПИЯ,НОРМОТИМИЧЕСКИЕ ПРЕПАРАТЫ,BIPOLAR DISORDER,PREVENTIVE THERAPY,NORMOTHYMIC DRUGS
File Description: text/html
-
14Academic Journal
Authors: Рожкова, Марина, Бобров, Александр
Subject Terms: ШИЗОАФФЕКТИВНОЕ РАССТРОЙСТВО, ДОМАНИФЕСТНЫЙ ЭТАП, ДЕПРЕССИЯ, БИПОЛЯРНОЕ РАССТРОЙСТВО, ГИПОМАНИЯ, ПАТОЛОГИЧЕСКИЕ ИНТЕРЕСЫ
File Description: text/html
-
15Academic Journal
Authors: Попович, Д., Рейнарес, М., Гойколеа, Х., Бонин, Ц., Гонзалес-пинто, А., Виета, Е.
File Description: text/html
-
16Academic Journal
Authors: МАРУТА Н.А., ЯВДАК И.А.
Subject Terms: БИПОЛЯРНОЕ РАССТРОЙСТВО,BIPOLAR DISORDER,ДЕПРЕССИЯ,DEPRESSION,ЭПИЛЕПТАЛ®,БіПОЛЯРНИЙ РОЗЛАД,ДЕПРЕСіЯ,ЕПіЛЕПТАЛ®,EPILEPTAL®
File Description: text/html
-
17Academic Journal
Authors: Фрайе, М.
Subject Terms: БИПОЛЯРНОЕ РАССТРОЙСТВО, ДЕПРЕССИЯ, ЛЕЧЕНИЕ, АНТИДЕПРЕССАНТЫ
File Description: text/html
-
18Academic Journal
Authors: Федотов, Дмитрий, Костюкова, Елена, Мосолов, Сергей
Subject Terms: БИПОЛЯРНОЕ РАССТРОЙСТВО, ПРОФИЛАКТИЧЕСКАЯ ТЕРАПИЯ, НОРМОТИМИЧЕСКИЕ ПРЕПАРАТЫ
File Description: text/html
-
19Academic Journal
Source: Социальная и клиническая психиатрия.
Subject Terms: БИПОЛЯРНОЕ РАССТРОЙСТВО, ПРОФИЛАКТИЧЕСКАЯ ТЕРАПИЯ, НОРМОТИМИЧЕСКИЕ ПРЕПАРАТЫ, 3. Good health
File Description: text/html
-
20Academic Journal
Source: Социальная и клиническая психиатрия.
Subject Terms: АЗЕНАПИН, АТИПИЧНЫЕ АНТИПСИХОТИКИ, ШИЗОФРЕНИЯ, БИПОЛЯРНОЕ РАССТРОЙСТВО, 3. Good health
File Description: text/html
